Abstract:Background and objective: Critically ill children may exhibit varied vancomycin pharmacokinetic parameters mainly due to altered protein binding, extracellular volume, and renal elimination. The objective of this study was to assess the pharmacokinetics of vancomycin in critically ill children and determine the optimum dose regimen. Methods: This was a cross-sectional study of critically ill children admitted to a pediatric intensive care unit. They received vancomycin dose of 15 mg/kg every 8 h for mild infections or every 6 h if infection was moderate or severe. A nonlinear mixed-effects modeling approach was applied in estimating pharmacokinetic parameters using Monolix 2019R2®. We performed Monte Carlo simulations to assess and optimize the dosing regimen using Simulx®. We used the ratio of the area under the concentration-time curve up to 24 h to minimum inhibitory concentration (AUC0-24/MIC) ≥ 400 as the pharmacokinetic-pharmacodynamic target. Results: Fifty-eight critically ill children with 145 concentrations were included in the present study. A one-compartment pharmacokinetic model with linear elimination described the concentration-time profile well. The estimated median (95% confidence intervals) volume of distribution (Vd) was 13.3 (10.8-16.5) l and clearance (CL) was 1.23 (1.03-1.45) l/h. Creatinine clearance significantly affected the CL of vancomycin. Monte Carlo simulations revealed that a dose of either 15 mg/kg 6 hourly or 20 mg/kg 8 hourly was likely to result into most critically ill children attaining the vancomycin lead pharmacokinetic-pharmacodynamic target. Conclusion: We established pharmacokinetic parameters of vancomycin for critically ill children. We also observed that the current dosing regimen practiced in the intensive care unit was inadequate for achieving the pharmacokinetic-pharmacodynamic target. We recommend vancomycin dose escalation in critically ill pediatric patients from 15 mg/kg 8 hourly (current dosing regimen) to either 6 hourly or 20 mg/kg 8 hourly with intense therapeutic drug monitoring for adverse effects.

Optimizing vancomycin dosing in pediatrics: a machine learning approach to predict trough concentrations in children under four years of age

An Ensemble Model for Prediction of Vancomycin Trough Concentrations in Pediatric Patients

Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates

Prediction of Vancomycin Dose on High-Dimensional Data Using Machine Learning Techniques

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children

Individualized medication model of vancomycin in patients with renal insufficiency using machine learning techniques

Application of machine learning combined with population pharmacokinetics to improve individual prediction of vancomycin clearance in simulated adult patients

Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.

Dose optimization and target attainment of vancomycin in children

Population pharmacokinetics and dosing optimization of vancomycin in infants, children and adolescents with augmented renal clearance

Vancomycin population pharmacokinetics analysis in Chinese paediatric patients with varying degrees of renal function and ages: development of new practical dosing recommendations

Modeling Approach to Optimizing Dose Regimen of Vancomycin for Chinese Pediatric Patients with Gram-Positive Bacterial Infections.

Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning

Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model

Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children

Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation

Desired Vancomycin Trough Concentration to Achieve an AUC0‐24/MIC ≥400 in Chinese Children with Complicated Infectious Diseases

Prediction of vancomycin plasma concentration in elderly patients based on multi-algorithm mining combined with population pharmacokinetics

A machine learning model that emulates experts' decision making in vancomycin initial dose planning

Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing

Vancomycin Population Pharmacokinetic Modeling in Children Using Bayesian Estimation and a Non Parametric Approach